| Yazarlar |
Prof. Dr. Oğuz ÖZÇELİK
Kastamonu Üniversitesi, Türkiye |
Halil Dogan
Firat Üniversitesi, Turkey |
|
Haluk Kelestimur
Firat Üniversitesi, Turkey |
| Özet |
| Background: Leptin, which has been identified as an antiobesity hormone, regulates body weight by controlling food intake and energy expenditure via the hypothalamic-pituitary-gonadal axis. It appears that leptin may be an important factor in obesity management. Orlistat, a pancreatic lipase inhibitor, could reduce fat absorption and promote weight loss due to leptin metabolism. Objective: The purpose of this study was to investigate the effects of orlistat therapy on serum leptin levels. Methods: Obese women (body mass index [BMI], 30 kg/m2) aged 18 to 50 years were randomly assigned to receive 12 weeks of oral treatment with diet-orlistat (120 mg TID) (DO group) or diet-placebo (DP group). During the treatment period, patients were asked to eat a balanced diet of -1200 to 1600 kcal/d. Body composition was determined by bioelectrical impedance. Serum leptin levels were measured using radioimmunoassay at baseline and at study end. Results: A total of 24 patients entered the study; 14 patients (mean [SE] BMI, 37.7 [1.1] kg/m2) received orlistat and 10 patients (mean [SE] BMI, 39.4 [1.3] kg/m2) received placebo. Compared with baseline, mean percentages of loss of body weight and fat mass after 12 weeks of treatment were significant in the DO group (9.1% and 14.8%, respectively; both P = 0.001) and in the DP group (9.5% and 17.6%; both P = 0.005). The between-group differences were not statistically significant. Mean (SE) serum leptin levels also decreased significantly after treatment in the DO group (16.2 [1.2] vs 9.0 [1.0] ng/mL; P = 0.001) and in the DP group (19.3 [2.1] vs 9.7 [1.4] ng/mL; P = 0.005). The between-group difference was not statistically significant. Conclusions: In this study of obese women, orlistat treatment was associated with a similar decrease in body weight, fat mass, and serum leptin levels as placebo over a 12-week period. In this regard, short-term orlistat therapy may not provide an additional effect on serum leptin levels, and reduction in leptin levels were closely related to the decrease in fat mass. © 2004. |
| Anahtar Kelimeler |
| leptin | obesity | orlistat | pharmacotherapy |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale |
| Dergi Adı | Curr. Ther. Res. Clin. Exp, |
| Dergi ISSN | 0011-393X |
| Dergi Tarandığı Indeksler | SSCI |
| Makale Dili | İngilizce |
| Basım Tarihi | 01-2004 |
| Cilt No | 65 |
| Sayı | 2 |
| Sayfalar | 127 / 137 |
| Doi Numarası | 10.1016/S0011-393X(04)90025-2 |
| Atıf Sayıları | |
| SCOPUS | 12 |
| Google Scholar | 17 |
